文献速递心脑血管急症

D-二聚体与中性粒细胞-淋巴细胞比值在疑似急性主动脉综合征患者中的潜在价值比较

Comparisons of potential values of D-dimer and the neutrophil- to-lymphocyte ratio in patients with suspected acute aortic syndrome.
PubMed 文献 · Am J Emerg Med · 2023-04-01
一句话结论在疑似急性主动脉综合征患者中,中性粒细胞-淋巴细胞比值(NLR)的鉴别诊断性能和临床效用优于D-二聚体,可能是D-二聚体的可靠替代标志物。

该研究回顾性纳入2018年6月至2021年12月在天津胸科医院因疑似急性主动脉综合征(AAS)就诊的连续患者697例,其中323例最终确诊AAS。比较基线D-二聚体和NLR对AAS的鉴别能力,采用ROC曲线下面积(AUC)、净重分类改善(NRI)和综合判别改善(IDI)评价,并用决策曲线分析(DCA)评估临床效用。结果显示NLR诊断AAS的AUC与D-二聚体相当(0.845 vs. 0.822,P > 0.05),但NRI为66.1%、IDI为12.4%(P < 0.001),且DCA显示NLR净获益更高;亚组分析结果相似。作者认为NLR作为更易获得的生物标志物,可能成为临床实践中筛查疑似AAS时D-二聚体的可靠替代。

要点

  • 在697例疑似AAS患者中,NLR诊断AAS的AUC为0.845,D-二聚体为0.822,两者比较P > 0.05,判别能力相当。
  • NLR较D-二聚体对AAS的鉴别性能更优,NRI为66.1%、IDI为12.4%(P < 0.001)。
  • DCA显示NLR较D-二聚体提供更高的净获益。
  • 按AAS不同分型进行的亚组分析观察到相似结果。
  • 作者认为NLR作为更易获得的生物标志物,可能成为临床实践中筛查疑似AAS时D-二聚体的可靠替代。

适用人群与场景

  • 2018年6月至2021年12月在天津胸科医院因疑似急性主动脉综合征(AAS)就诊的连续患者,共697例,其中323例最终确诊AAS。

研究设计与关键结果

  • 研究为回顾性研究,纳入疑似AAS的连续患者697例,最终确诊AAS 323例。
  • AAS患者基线NLR和D-二聚体水平均高于非AAS患者。
  • NLR诊断AAS的AUC为0.845,D-二聚体为0.822,两者比较P > 0.05。
  • NLR较D-二聚体对AAS的鉴别性能更优,NRI为66.1%、IDI为12.4%(P < 0.001)。
  • DCA显示NLR较D-二聚体提供更高的净获益。
  • 按AAS不同分型进行的亚组分析观察到相似结果。

证据类型、等级与局限

  • 证据类型:回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,NLR作为更易获得的生物标志物,可能成为临床实践中筛查疑似AAS时D-二聚体的可靠替代。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: This study aimed to investigate and compare the discriminative performance and clinical utility of D-dimer and the neutrophil-to-lymphocyte ratio (NLR) in the early differential diagnosis of acute aortic syndrome (AAS).

METHODS: The consecutive patients presenting to Tianjin Chest Hospital for suspected AAS were retrospectively investigated between June 2018 and December 2021. The baseline values of D-dimer and NLR were analyzed and compared in the study population. The discriminative ability of D-dimer and NLR was illustrated and compared using the area under the receiver operating characteristic (ROC) curve (AUC), net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Clinical utility was evaluated by means of decision curve analysis (DCA).

RESULTS: In the study period, a total of 697 participants suspected of having AAS were enrolled and 323 had a final diagnosis of AAS. The baseline level of NLR as well as D-dimer was higher in patients with AAS. The use of NLR showed excellent overall diagnostic performance for AAS with a comparable AUC to that of D-dimer (0.845 vs. 0.822, P > 0.05). The reclassification analyses further confirmed that NLR had better discriminative properties for AAS with a significant NRI of 66.1% and IDI of 12.4% (P < 0.001). Moreover, NLR provided higher net benefit than D-dimer as shown by DCA. Similar results were observed in subgroup analyses according to the different classes of AAS.

CONCLUSIONS: NLR outperformed D-dimer with improved discriminative performance and superior clinical utility in identifying AAS. As a more readily available biomarker, NLR may be a reliable alternative to D-dimer for the screening of suspected AAS in clinical practice.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Zhang H, Yuan N, Guo J, et al. Comparisons of potential values of D-dimer and the neutrophil- to-lymphocyte ratio in patients with suspected acute aortic syndrome. Am J Emerg Med. 2023. PMID: 37058980. doi:10.1016/j.ajem.2023.03.059

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。